Table 2.
Serotype-specific average per-dose take rates for tOPV and bOPV determined in the clinical trials that compared both vaccines, and assumed in the DEB and global models
| Setting | tOPV serotype | bOPV serotype | ||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 1 | 2 | 3 | |
| Clinical trials | ||||||
| Central and Southern India [25], 2 doses at 0 and 30 days of age | 0.39 | 0.70 | 0.31 | 0.62 | 0.06 | 0.49 |
| Bangladesh [26], 3-doses at 6, 10, and 14 weeks of age) | 0.57 | 0.65 | 0.51 | 0.70 | 0.06 | 0.65 |
| Calibrated DEB model within ranges from literature [17, 21] | ||||||
| Northwest Nigeria [4, 6, 9, 17, 19] | 0.45 | 0.70 | 0.35 | 0.54 | 0 | 0.54 |
| Northern India [5, 9, 17, 19] | 0.35 | 0.60 | 0.27 | 0.42 | 0 | 0.42 |
| Global model assumptions based on calibrated DEB model [20] | ||||||
| Lowest tier (e.g., Northern India) | 0.35 | 0.60 | 0.27 | 0.42 | 0 | 0.42 |
| Second tier (e.g., Northern Pakistan) | 0.40 | 0.65 | 0.32 | 0.50 | 0 | 0.50 |
| Third tier (e.g., Northwest Nigeria) | 0.45 | 0.70 | 0.35 | 0.54 | 0 | 0.54 |
| Fourth tier (e.g., Brazil) | 0.50 | 0.72 | 0.40 | 0.60 | 0 | 0.60 |
| Fifth tier (e.g., Philippines, Turkey) | 0.55 | 0.73 | 0.45 | 0.70 | 0 | 0.70 |
| Sixth tier (e.g., Russia, middle-income China) | 0.60 | 0.74 | 0.50 | 0.75 | 0 | 0.75 |
| Seventh tier (e.g., upper-income China, Israel) | 0.65 | 0.75 | 0.55 | 0.80 | 0 | 0.80 |